Results 211 to 220 of about 2,200,340 (304)

Individual and Societal Economic Burden of Atopic Dermatitis: A Nationwide Cohort Study

JEADV Clinical Practice, EarlyView.
Using nationwide registry‐based data, this study estimates the economic burden of atopic dermatitis. Each individual with atopic dermatitis incurs an annual excess cost of €2172, driven mainly by foregone income rather than direct healthcare expenditure. ABSTRACT Background Atopic dermatitis (AD) imposes a significant economic burden for individuals as
Martino Renzi‐Lomholt, Zarqa Ali, Simon Francis Thomsen, Anders Løkke, Ole Hilberg, Rikke Ibsen, Charlotte Suppli Ulrik, Kjell Erik Julius Håkansson   +7 more
wiley   +1 more source

Pathogenic group 2 innate lymphoid cells as drivers of lung fibrosis in severe asthma. [PDF]

Front Immunol
Matsuda M, Sannomiya Y, Kaminuma O, Nabe T.   +3 more
europepmc   +1 more source

Nail Psoriasis in Pediatric Populations

JEADV Clinical Practice, EarlyView.
ABSTRACT Pediatric nail psoriasis is an under‐recognized yet clinically important manifestation of psoriasis with both diagnostic and prognostic implications. Nail involvement in children is associated with greater overall disease severity, poorer treatment outcomes, and is a predictor for the development of psoriatic arthritis.
Aditya K. Gupta, Elizabeth Teasell, Federico Quadrelli, Bianca Maria Piraccini   +3 more
wiley   +1 more source

High degree of remission in pediatric severe asthma patients treated with biologics in a real-world setting. [PDF]

World Allergy Organ J
Cerda Reyes S, Larenas-Linnemann D, Castillón Benavides NK.   +2 more
europepmc   +1 more source

Real World Use of the IL‐36 Receptor Antagonist Spesolimab: A Systematic Review and Analysis

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Spesolimab, an interleukin‐36 receptor antagonist, is approved for the treatment and prevention of generalised pustular psoriasis (GPP) flares. Its use has increasingly been reported in real‐world settings for both GPP and other inflammatory dermatoses.
Sophia A. Mense, Nicole Bavaro, Aashna Farishta, Jiaqi Chen, Raj Chovatiya   +4 more
wiley   +1 more source

Characteristics of severe asthma patients with biologic treatment in the Swedish National Airway Register. [PDF]

Eur Clin Respir J
Sundbom F, Palm A, Emilsson ÖI, Stridsman C.   +3 more
europepmc   +1 more source

Treatment of Severe Asthma [PDF]

BMJ, 1955
openaire   +2 more sources

Mechanism of RNA‐Binding Protein ELAVL1 in Promoting Th2 Cell Differentiation Through Stabilizing CPA3 mRNA in Allergic Rhinitis

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study aimed to elucidate the role of the RNA‐binding protein embryonic lethality abnormal vision‐like protein 1 (ELAVL1) in the pathogenesis of allergic rhinitis (AR), specifically by investigating its potential to promote T helper 2 (Th2) cell differentiation by regulating the stability of carboxypeptidase A3 (CPA3) mRNA.
Meng‐Ya Liu, Hong‐Bing Yao, Cheng Chen   +2 more
wiley   +1 more source

Relationships Between Bronchodilator Reversibility and Mannitol Airway Hyperresponsiveness in Severe Asthma. [PDF]

Clin Transl Allergy
Suter P, Greig R, Chan R, Lipworth BJ.
europepmc   +1 more source